FDA approvals and Icahn exit drive Friday stock moves

Corporate ActionRegulation

โดย Seeking Alpha·

Summary · why it matters

Stock index futures were mixed on Friday as traders awaited Federal Reserve Chair Kevin Warsh's speech at the Jackson Hole Symposium, with several individual stocks moving on regulatory and corporate news. JetBlue Airways rose 0.82% in premarket trade after activist investor Carl Icahn lowered his stake below the level required to maintain board representation, prompting Icahn Enterprises representatives Jesse Lynn and Steven Miller to step away from the board, leaving it with 11 members, 10 of whom are independent. Gilead Sciences gained 0.64% after the U.S. Food and Drug Administration approved its once-daily oral antiviral Bixlenvo as the smallest single-tablet regimen for treating HIV in adults, combining its once-daily HIV pill bictegravir with its twice-yearly pre-exposure prophylaxis option lenacapavir. Eli Lilly rose 0.76% after the FDA approved a label expansion for its blockbuster GLP-1 drug Mounjaro to lower the risk of major adverse cardiovascular events, including stroke, in adults with type 2 diabetes. Moderna fell 1.93% after pricing $2.6 billion of 0.00% convertible senior notes due 2032 in a private placement, upsized from the previously announced $2 billion, with an option for initial purchasers to buy up to an additional $400 million of the notes.